Last reviewed · How we verify

NCT05229445: CGM-IBC

A Continuous Glucose Monitor Based Insulin Bolus Calculator

Completed NA Last updated 13 October 2022
What this trial tests

NA trial testing continuous glucose monitor based insulin bolus calculator in Diabetes Mellitus, Type 2 in 27 participants. Completed in 28 September 2022.

Timeline
5 July 2022
Primary endpoint
28 September 2022
28 September 2022

Quick facts

Lead sponsorWelldoc
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment27
Start date5 July 2022
Primary completion28 September 2022
Estimated completion28 September 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Welldoc

Who can join

18 and older, any sex, with Diabetes Mellitus, Type 2 or Diabetes Mellitus, Type 1. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study examines the safety of an app-based insulin bolus calculator that utilizes glucose values from a continuous glucose monitor

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

Other Welldoc trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05229445.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing